Ablation of Gprc6a in mice results in obesity, glucose intolerance, hepatic steatosis, sarcopenia and insulin resistance [6], and deletion of Ocn, a natural ligand for GPRC6A leads to an identical phenotype to Gprc6a-/- mice [7]. Here, GPRC6A is linked to fatty liver disease.